COVID-19 Supplemental Appropriations Act

March 11, 2020

On March 6, the President signed the Coronavirus Preparedness and Response Supplemental Appropriations Act. This Act allocates $8.3 billion to fund the government’s response to COVID-19, including vaccine development, support for state and local government response efforts, and assistance for affected small businesses.

This Act directs funding toward:

- Research and development of vaccines, therapeutics, and diagnostics to prevent and treat the effects of COVID-19 ($3B, 37%).
- CDC ($2.2B, 27%) to support public health agencies to prevent, prepare for, and respond to the outbreak, and to research and develop a vaccine for this novel disease.
- Healthcare Preparedness, Pharmaceuticals and Medical Supplies, Community Health Centers ($1B, 12%) for procurement of pharmaceuticals and medical supplies, to support healthcare preparedness, and to improve medical surge capacity.
- Emergency Telehealth Waiver ($500M, 6%) to allow the HHS to waive certain Medicare telehealth restrictions.
COVID-19 Supplemental Appropriations Act

Total funding totals $8.3 billion, with the largest directed toward the CDC and vaccines, therapeutics, and diagnostics development.

**HR 6074 Funding Overview**

- **37%** for **Global Health Response**
- **27%** for **Vaccines, Therapeutics, and Diagnostics**
- **12%** for **Humanitarian Assistance**
- **9%** for **Other**
- **6%** for **Healthcare Preparedness**
- **5%** for **Emergency Telehealth Waiver**
- **4%** for **Oversight of activities related to coronavirus preparedness and response**
- **6%** for **Reimbursing HHS for funds that were temporarily transferred to support the CDC**
- **12%** for **Supporting health systems overseas**
- **9%** for **The Small Business Administration to administer loan subsidies to help small businesses that have been impacted by the outbreak**

Source: HR 6074 Bill Summary
This publication is provided for informational purposes only. The opinions expressed herein are those of the individual authors, and do not represent the opinions of Berkeley Research Group, LLC or any of its other employees or affiliates. The information provided herein is not intended to and does not constitute legal, financial, investment, accounting, tax, or any other type of professional advice, and should not be relied on as such by any recipient. None of the information contained herein should be used as a substitute for consultation with competent advisors. All information contained herein is provided “as is” without any express or implied warranty of any kind. While reasonable efforts have been taken to present accurate factual data from a variety of sources, no representation or assurances as to the accuracy of information or data published or provided by third parties and contained herein is made. Berkeley Research Group, LLC, and its affiliates, and their respective officers, directors, members and employees shall have no liability in contract, tort or otherwise to any third party. The information set forth in this publication is for the internal use of the subscriber. The information contained herein is proprietary, and any duplication or distribution of such material to any third party is expressly prohibited absent the prior written consent of Berkeley Research Group, LLC. The copyright for any material created by the authors and all other rights are reserved.

Information for this analysis was obtained from public documents